指南与共识泌尿生殖腹部MR

肾脏多参数MRI与MR尿路造影的影像检查方案:法国泌尿生殖影像学会共识会议结果

Imaging protocols for renal multiparametric MRI and MR urography: results of a consensus conference from the French Society of Genitourinary Imaging.
指南 / 共识 · Eur Radiol · 2020-01-03

法国泌尿生殖影像学会采用两轮Delphi调查加面对面会议形成共识,42名专家完成两轮调查;mpMRI问卷84条中56条(67%)、MRU问卷71条中44条(62%)达成共识,推荐mpMRI无需注射呋塞米,MRU须在注射对比剂前静脉注射呋塞米。

要点

  • mpMRI无需注射呋塞米,序列含T2WI、双回波化学位移、DWI(最大b值1000 s/mm2)及脂肪抑制单次团注多期增强。
  • MRU须在注射对比剂前静脉注射呋塞米,检查前患者应排空膀胱。
  • MRU序列含T2WI、快速解剖T1/T2WI、DWI(最大b值1000 s/mm2)及脂肪抑制单次团注多期增强(含排泄期)。

核心结论

  • 该专家共识会议为肾脏、输尿管和膀胱的MRI标准化提供推荐意见。
  • mpMRI用于肾脏肿块的定性,MRU用于膀胱和集合系统的成像。

研究设计与样本

  • 法国泌尿生殖影像学会组织Delphi共识会议,采用两轮Delphi调查后召开面对面会议。
  • 分别针对肾脏mpMRI和MRU发放两份独立问卷,共识采用预先设定的标准严格界定。
  • 42名泌尿影像专家完成两轮调查,两轮之间无人员流失。

诊断标准与关键数值

  • mpMRI问卷84条陈述中56条(67%)达成最终共识,MRU问卷71条陈述中44条(62%)达成最终共识。
  • mpMRI共识认为无需注射呋塞米,方案应包括T2加权成像、双化学位移成像、DWI(使用多个b值,最大b值1000 s/mm2)及脂肪抑制单次团注多期(平扫、皮髓质期、肾实质期)增强成像,注射后超过10分钟的延迟成像被判定为可选。
  • MRU共识要求患者检查前排空膀胱,方案必须包括T2加权成像、解剖快速T1/T2加权成像、DWI(使用多个b值,最大b值1000 s/mm2)及脂肪抑制单次团注多期(平扫、皮髓质期、肾实质期、排泄期)增强成像。
  • MRU共识认为在注射对比剂前静脉注射呋塞米是强制性的,重度T2加权类胰胆管成像被判定为可选。

临床应用与阅片要点

  • 肾脏mpMRI定性肾脏肿块时按共识不注射呋塞米,常规纳入T2WI、双化学位移、DWI及多期增强,延迟期可酌情选择。
  • MRU检查前让患者排空膀胱,并在注射对比剂前静脉注射呋塞米,增强序列需覆盖排泄期,重度T2加权成像可选。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop technical guidelines for magnetic resonance imaging aimed at characterising renal masses (multiparametric magnetic resonance imaging, mpMRI) and at imaging the bladder and upper urinary tract (magnetic resonance urography, MRU).

METHODS: The French Society of Genitourinary Imaging organised a Delphi consensus conference with a two-round Delphi survey followed by a face-to-face meeting. Two separate questionnaires were issued for renal mpMRI and for MRU. Consensus was strictly defined using a priori criteria.

RESULTS: Forty-two expert uroradiologists completed both survey rounds with no attrition between the rounds. Fifty-six of 84 (67%) statements of the mpMRI questionnaire and 44/71 (62%) statements of the MRU questionnaire reached final consensus. For mpMRI, there was consensus that no injection of furosemide was needed and that the imaging protocol should include T2-weighted imaging, dual chemical shift imaging, diffusion-weighted imaging (use of multiple b-values; maximal b-value, 1000 s/mm2) and fat-saturated single-bolus multiphase (unenhanced, corticomedullary, nephrographic) contrast-enhanced imaging; late imaging (more than 10 min after injection) was judged optional. For MRU, the patients should void their bladder before the examination. The protocol must include T2-weighted imaging, anatomical fast T1/T2-weighted imaging, diffusion-weighted imaging (use of multiple b-values; maximal b-value, 1000 s/mm2) and fat-saturated single-bolus multiphase (unenhanced, corticomedullary, nephrographic, excretory) contrast-enhanced imaging. An intravenous injection of furosemide is mandatory before the injection of contrast medium. Heavily T2-weighted cholangiopancreatography-like imaging was judged optional.

CONCLUSION: This expert-based consensus conference provides recommendations to standardise magnetic resonance imaging of kidneys, ureter and bladder.

KEY POINTS: • Multiparametric magnetic resonance imaging (mpMRI) aims at characterising renal masses; magnetic resonance urography (MRU) aims at imaging the urinary bladder and the collecting systems. • For mpMRI, no injection of furosemide is needed. • For MRU, an intravenous injection of furosemide is mandatory before the injection of contrast medium; heavily T2-weighted cholangiopancreatography-like imaging is optional.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Rouvière O, Cornelis F, Brunelle S, et al. Imaging protocols for renal multiparametric MRI and MR urography: results of a consensus conference from the French Society of Genitourinary Imaging. Eur Radiol. 2020. PMID: 31900706. doi:10.1007/s00330-019-06530-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。